Announcement PDF SPACETALK LTD ACN 091 351 530 NOTICE OF ANNUAL GENERAL MEETING Notice is given that the Meeting will be held at: TIME: 11:00 a.m. (AEDT) DATE: Thursday, 19 November 2026 PLACE: Spacetalk Ltd, Suite 2, Level 9, 80-82 Pitt Street, Sydney, NSW The business of the Meeting affects your shareholding and your vote is important. Shareholders are urged to attend meeting and or vote by lodging the Proxy Form attached to this Notice. This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting. The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 7.00 p.m. (AEDT) on Tuesday, 17 November 2026. 2 B US I N E S S O F TH E M EE T I N G AGENDA FINANCIAL STATEMENTS AND REPORTS To receive and consider the annual financial report of the Company for the financial year ended 30 June 2026 together with the declaration of the Directors, the Director’s report, the Remuneration Report and the auditor’s report. 1. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT To consider and, if thought fit, to pass, with or without amendment, the following resolution as a non-binding resolution: “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company’s annual financial report for the financial year ended 30 June 2026.” Note: the vote on this Resolution is advisory only and does not bind the Directors or the Company. 2. RESOLUTION 2 – ELECTION OF DIRECTOR – ANDREW GROVER To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That , Andrew Grover, who having previously been appointed to fill a casual vacancy, retires in accordance with Listing Rule 14.4 and clause 19.2 of the Company’s Constitution and who offers himself for election, is elected as a Director of the Company.” 3. RESOLUTION 3 – APPROVAL OF ISSUE OF PERFORMANCE RIGHTS TO GEORG CHMEIL To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the issue and allotment of 319,203 Performance Rights to Mr Georg Chmiel (or his nominee) under the Company’s Equity Incentive Plan, on the terms and conditions set out in the Explanatory Statement” 4. RESOLUTION 4 – APPROVAL OF ISSUE OF PERFORMANCE RIGHTS TO MIKE RANN To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the issue and allotment of 182,402 Performance Rights to the Hon Mike Rann AC (or his nominee) under the Company’s Equity Incentive Plan, on the terms and conditions set out in the Explanatory Statement” 5. RESOLUTION 5 – APPROVAL OF ISSUE OF PERFORMANCE RIGHTS TO JOHN BIRD To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the issue and allotment of 136,801 Performance Rights to the Mr John Bird (or his nominee) under the Company’s Long Term Incentive Plan, on the terms and conditions set out in the Explanatory Statement” 3 6. RESOLUTION 6 – APPROVAL OF ISSUE OF PERFORMANCE RIGHTS TO ANDREW GROVER To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the issue and allotment of 45,600 Performance Rights to the Mr Andrew Grover (or his nominee) under the Company’s Long Term Incentive Plan, on the terms and conditions set out in the Explanatory Statement” 7. RESOLUTION 7 – APPROVAL OF 10% PLACEMENT FACILITY To consider and, if thought fit, to pass, with or without amendment, the following resolution as a Special Resolution: “That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, Shareholders approve the Company having additional capacity to issue Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) (10% Share Placement Capacity) calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 and on the terms and conditions set out in the Explanatory Statement.” Dated: 21 October 2026 Hasaka Martin Company Secretary By Order of the Board 4 Voting Prohibitions In accordance with sections 250BD and 250R of Corporations Act, voting prohibitions apply to the following persons: Resolution 1 – Adoption of Remuneration Report A vote on this Resolution must not be cast (in any capacity) by or on behalf of either of the following persons: (a) a member of the Key Management Personnel, details of whose remuneration are included in the Remuneration Report; or (b) a Closely Related Party of such a member. However, a person (the voter) described above may cast a vote on this Resolution as a proxy if the vote is not cast on behalf of a person described above and either: (a) the voter is appointed as a proxy by writing that specifies the way the proxy is to vote on this Resolution; or (b) the voter is the Chair and the appointment of the Chair as proxy: (i) does not specify the way the proxy is to vote on this Resolution; and (ii) expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with the remuneration of a member of the Key Management Personnel. Resolutions 3, 4, 5 and 6 - Approval of Issue of Performance Rights to Georg Chmiel, Mike Rann, Andrew Grover and John Bird A person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if: (a) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and (b) the appointment does not specify the way the proxy is to vote on this Resolution. However, the above prohibition does not apply if: (c) the proxy is the Chair; and (d) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel. Voting Exclusion Statements In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the Resolution set out below by or on behalf of the following persons: Resolution 3 - Approval of Issue of Performance Rights to Georg Chmiel All persons referred to in Rule 10.14.1, 10.14.2 or 10.14.3, who are eligible to participate in the Long Term Incentive Plan.. Resolution 4- Approval of Issue of Performance Rights to Mike Rann All persons referred to in Rule 10.14.1, 10.14.2 or 10.14.3, who are eligible to participate in the Long Term Incentive Plan. Resolution 5 - Approval of Issue of Performance Rights to John Bird All persons referred to in Rule 10.14.1, 10.14.2 or 10.14.3, who are eligible to participate in the Long Term Incentive Plan. Resolution 6 - Approval of Issue of Performance Rights to Andrew Grover All persons referred to in Rule 10.14.1, 10.14.2 or 10.14.3, who are eligible to participate in the Long Term Incentive Plan. Resolution 7 - Approval of 10% Placement Facility Any person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of Shares); or any associate of such person. However, this does not apply to a vote cast in favour of the Resolution by: (a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or (b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: 5 (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and (ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way. Voting by proxy To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in accordance with the instructions set out on the Proxy Form. In accordance with section 249L of the Corporations Act, Shareholders are advised that: • each Shareholder has a right to appoint a proxy; • the proxy need not be a Shareholder of the Company; and • a Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the Shareholder appoints two proxies and the appointment does not specify the proportion or number of the member’s votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes. Shareholders and their proxies should be aware that: • if proxy holders vote, they must cast all directed proxies as directed; and • any directed proxies which are not voted will automatically default to the Chair, who must vote the proxies as directed. Chair’s Voting Intention The Chair intends to vote all undirected proxies in favour of all resolution. Voting in person To vote in person, attend the Meeting at the time, date and place set out above. Should you wish to discuss the matters in this Notice please do not hesitate to contact the Company Secretary, Hasaka Martin, at hasaka.martin@singletoncosec.com.au. 6 E X PL A N A T O R Y S T A T E M E N T This Explanatory Statement has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to vote for the Resolutions. 1. FINANCIAL STATEMENTS AND REPORTS In accordance with the Corporations Act, the business of the Meeting will include receipt and consideration of the annual financial report of the Company for the financial year ended 30 June 2026 together with the declaration of the Directors, the Directors’ report, the Remuneration Report and the auditor’s report. The Company will not provide a hard copy of the Company’s annual financial report to Shareholders unless specifically requested to do so. The Company’s annual financial report is available on its website on the Company’s investor relations website at https://investorhub.spacetalk.co . 2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT 2.1 General The Corporations Act 2001 (Cth) (the Act) requires that at a listed company’s annual general meeting, a resolution that the remuneration report to be adopted must be put to the shareholders. However, such a resolution is advisory only and does not bind the company or the directors of the company. The remuneration report sets out the company’s remuneration arrangements for the directors and senior management of the company. The remuneration report is part of the directors’ report contained in the annual financial report of the company for a financial year. The chair of the meeting must allow a reasonable opportunity for its shareholders to ask questions about or make comments on the remuneration report at the annual general meeting. 2.2 Voting consequences A company is required to put to its shareholders a resolution proposing the calling of another meeting of shareholders to consider the appointment of directors of the company (Spill Resolution) if, at consecutive annual general meetings, at least 25% of the votes cast on a remuneration report resolution are voted against adoption of the remuneration report and at the first of those annual general meetings a Spill Resolution was not put to vote. If required, the Spill Resolution must be put to vote at the second of those annual general meetings. If more than 50% of votes cast are in favour of the Spill Resolution, the company must convene a shareholder meeting (Spill Meeting) within 90 days of the second annual general meeting. All of the directors of the company who were in office when the directors' report (as included in the company’s annual financial report for the most recent financial year) was approved, other than the managing director of the company, will cease to hold office immediately before the end of the Spill Meeting but may stand for re-election at the Spill Meeting. Following the Spill Meeting those persons whose election or re-election as directors of the company is approved will be the directors of the company. 2.3 Previous voting results At the Company’s previous annual general meeting the votes cast against the remuneration report were less than 25%. Accordingly, the Spill Resolution is not relevant for this Meeting. 7 3. RESOLUTION 2 – ELECTION OF DIRECTOR – ANDREW GROVER 3.1 General Listing Rule 14.4 and clause 19.2 of the Constitution provide that, a director appointed by directors to fill a casual vacancy, must not hold office (without election) past the next annual general meeting. On 8 April 2026, Andrew Grover was appointed as an independent non-executive Director of the Company. Mr Grover having been appointed by the directors, retires in accordance with Listing Rule 14.4 and clause 19.2 of the Constitution, and offers himself for election. 3.2 Qualifications, experience and other material directorships Andrew is an experienced public company executive, entrepreneur and investor with extensive experience across healthcare, technology, consumer and financial services sectors. He is Executive Chair of Echo IQ Ltd (ASX: EIQ), where he led the company’s transformation into a US focused AI diagnostics business, achieving FDA clearance and establishing a US-based leadership team to drive commercialisation and growth. Andrew also serves as Non-Executive Chairman of Nutritional Growth Solutions (ASX: NGS), where he is leading a strategic rebuild including governance reform, operational restructuring and acquisition strategy. He has founded and exited multiple high-growth businesses and is recognised for strategic repositioning, capital markets execution and scaling organisations for long-term value creation. 3.3 Technical information required by Listing Rule 14.1A If this Resolution is passed, Mr Grover will be re-elected as an independent Director. If this Resolution is not passed, Mr. Grover will not continue in their role as independent Director. The Company may seek nominations or otherwise identify suitably qualified candidates to join the Company. 3.4 Directors Recommendation The Directors (excluding Mr Grover) are of the view that Mr Grover has the skills, knowledge, experience and capabilities required by the Board. The Directors (other than Mr Grover) recommend that Shareholders vote in favour of this Resolution. 4. RESOLUTIONS 3, 4, 5 AND 6 – APPROVAL OF ISSUE OF PERFORMANCE RIGHTS TO GEORG CHMIEL, JOHN BIRD AND ANDREW GROVER. 4.1 General Non-Executive Directors agreed to a variation to the terms of their appointment, such that a portion of their directors’ fees is payable in Performance Rights rather than cash, subject to Shareholder approval. The proposed grant to the Non-Executive Directors is to link their interests to shareholder value creation and to encourage the long-term sustainable growth of the Company, as well as to assist with conservation of cash. Subject to Shareholders approval, the Company proposes to grant Performance Rights to each of the following Non-Executive Directors (or their nominee): • 319,203 Performance Rights to Mr Georg Chmiel (or his nominee), Chair and non- executive Director (Resolution 3); • 182,402 Performance Rights to the Mr Mike Rann (or his nominee), Non-Executive Director (Resolution 4); • 136,801 Performance Rights to Mr John Bird (or his nominee), Non-Executive Director (Resolution 5);and • 45,600 Performance Rights to Mr Andrew Grover (or his nominee), Non-Executive Director (Resolution 6). 8 The quantum of the Performance Rights is to be determined by applying a VWAP calculation over the period in which the remuneration applicable to the Performance Rights is earned. For the purposes of these Resolutions the calculation is based upon the period from 1 July 2025 until 30 June 2026 (inclusive). Listing Rule 10.14 provides that a listed company must not issue equity securities to a Director of the Company, or a person meeting the description in Listing Rule 10.14.3, under an employee incentive scheme unless the issue has been approved by Shareholders. Once Shareholder approval is obtained pursuant to Listing Rule 10.14, the Company is entitled to rely on Listing Rule 10.12, exception 8 as an exception to any requirement that may otherwise apply requiring Shareholder approval under Listing Rule 10.11. Similarly, Shareholder approval will not be required under Listing Rule 7.1, as Listing Rule 7.2 exception 14 applies. 4.2 Information required by Listing Rule 14.1A If these Resolutions are approved, the Company will be able to proceed with the issue of the Performance Rights to Mr Georg Chmiel, Mr Mike Rann, Mr John Bird and Mr Andrew Grover. If these Resolutions are not approved, the Company will not be able to proceed with the issue and the Company will be required to pay the equivalent value in cash. 4.3 Information required under Listing Rule 10.15 REQUIRED INFORMATION Resolution 3 Resolutions 4, 5 and 6 Name of the person to whom Securities will be issued Mr. Georg Chmiel Mr. Mike Rann, Mr. John Bird and Mr. Andrew Grover. Category of person under Listing Rule 10.14 Mr. Chmiel falls within the category set out in Listing Rule 10.14.1 by virtue of being a Director of the Company. Any nominee(s) of Mr. Chmiel who receive Securities may constitute ‘associates’ for the purposes of Listing Rule 10.14.2. Mr. Rann, Mr. Bird and Mr. Grover fall within the category set out in Listing Rule 10.14.1 as they are Directors of the Company. Any nominee(s) of Mr. Rann, Mr. Bird or Mr. Grover who receive Securities may constitute ‘associates’ for the purposes of Listing Rule 10.14.2. Number of Securities and class to be issued 319, 203 Performance Rights will be issued. 182,402 Performance Rights will be issued to Mr. Rann. Mr. Bird and Mr. Grover will receive a pro- rata amount relative to their length of service over the 2026 financial year. 136,801 Performance Rights will be issued to Mr. Bird. 45,600 Performance Rights will be issued to Mr. Grover. Remuneration package The total remuneration package for Non- Executive Chair is: • $96,000 per annum in cash; • $35,000 per annum in performance rights (the subject of this Resolution). The total remuneration package for each of the Non-Executive Directors is: • $45,000 per annum in cash; • $20,000 per annum in performance rights (the subject of this Resolution); and • Statutory superannuation. Mr. Bird was appointed as a Non- executive Director on 15 September 2025. And Mr. Gover was appointed 8 April 2026. Mr. Bird and Mr. Grover receive a pro- rated amount of performance rights equal to the proportion of 2026 financial year for which they served as a director. 9 REQUIRED INFORMATION Resolution 3 Resolutions 4, 5 and 6 Securities previously issued to the recipient/(s) under the Plan 341,145 Performance Rights have previously been issued to Mr. Chmiel for nil cash consideration under the Plan. 205,485 Performance Rights have previously been issued to Mr. Rann for nil cash consideration under the Plan. No performance rights or other securities have been issued to Mr. John Bird, or Mr. Andrew Grover, under the Plan. Terms of Securities The Performance Rights will vest one business day after the grant and expire five years after the date of grant. Each vested Performance Right may be converted to a Share for nil consideration, upon the holder’s election. The Performance Rights are issued under the Long Term Incentive Plan rules which are set out in Annexure A to this Notice. Consideration of type of Security to be issued Nil cash consideration is paid for the Performance Rights. The securities are issued as part of the 2026 financial directors fees. Valuation The Company values the Performance Rights at $35,000 per annum in performance rights, calculated based on the VWAP of the Company’s shares over the 2026 financial year ($0.1096). The Company values the Performance Rights at $20,000 per annum in performance rights, calculated based on the VWAP of the Company’s shares over the 2026 financial year ($0.1096). Date(s) on or by which the Securities will be issued The Company expects to issue the Securities within 5 Business Days of the Meeting. In any event, the Company will not issue any Securities later than three years after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules). Issue price of Securities The Performance Rights will be issued at a nil issue price. Material terms of the Plan A summary of the material terms and conditions of the Plan is set out in Annexure A. Material terms of any loan No loan is being made in connection with the acquisition of the Securities. Additional Information Details of any Securities issued under the Plan will be published in the annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under Listing Rule 10.14. Any additional persons covered by Listing Rule 10.14 who become entitled to participate in an issue of Securities under the Plan after this Resolution is approved and who were not named in this Notice will not participate until approval is obtained under Listing Rule 10.14. Voting exclusion statement A voting exclusion statement applies to this Resolution. Voting prohibition statement. A voting prohibition statement applies to this Resolution. 4.4 Directors Recommendation The Directors (excluding Mr. Chmiel for Resolution 3, Mr Rann for Resolution 4, Mr Bird for Resolution 5 and Mr Grover for Resolution 6) recommend that Shareholders vote in favour of this Resolution. 10 5. RESOLUTION 7 – APPROVAL OF 10% PLACEMENT FACILITY 5.1 General Broadly speaking, and subject to a number of exceptions, ASX Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its Shareholders over any 12-month period to 15% of the fully paid ordinary securities it had on issue at the start of that period. However, under ASX Listing Rule 7.1A, an eligible entity can seek approval from its Shareholders, by way of a special resolution passed at its annual general meeting, to increase this 15% limit by an extra 10% (10% Share Placement Capacity) bringing the total combined potential placement capacity to 25%. An ‘eligible entity’ for the purpose of ASX Listing Rule 7.1A is an entity that is not included in the S&P/ASX 300 Index and has a market capitalisation of $300 million or less. At the date of this Notice, the Company is an eligible entity and anticipates it will remain an eligible entity at the date of the Meeting. Resolution 7 seeks Shareholder approval, by way of special resolution, for the Company to have the additional 10% Share Placement Capacity provided for in ASX Listing Rule 7.1A to issue Equity Securities without Shareholder approval. Resolution 7 is a special resolution which requires approval of at least 75% of the votes cast by Shareholders entitled to vote be in favour of the Resolution. 5.2 Information required by Listing Rule 14.1A If Resolution 7 is passed, the Company will be able to access the 10% Share Placement Capacity allowing it to issue Equity Securities up to the combined 25% limit in ASX Listing Rules 7.1 and 7.1A without any further Shareholder approval. If Resolution 7 is not passed, the Company will not be able to access the additional 10% Share Placement Capacity provided for in ASX Listing Rule 7.1A and will remain subject to its 15% limit under ASX Listing Rule 7.1. 5.3 Additional Information required by ASX Listing Rule 7.3A In accordance with ASX Listing Rule 7.3A, the following information is provided: Minimum price The price at which the Equity Securities may be issued under the 10% Share Placement Capacity must not be less than 75% of the volume weighted average price of an existing quoted class of the Company’s Equity Securities, calculated over 15 trading days on which trades in that class were recorded immediately before: • the date on which the price at which the Equity Securities are to be issued is agreed; or • if the Equity Securities are not issued within 10 trading days of the date in paragraph (i), the date on which the Equity Securities are issued. Potential risk of economic and voting dilution If Resolution 7 is approved and Equity Securities are issued under the 10% Share Placement Capacity, the existing Shareholders’ economic and voting power in the Company will be diluted. There is a risk that: • the market price for the Equity Securities in that class may be significantly lower on the issue date than on the date of the approval under ASX Listing Rule 7.1A; and • the Equity Securities may be issued at a price that is at a discount to the market price for those Equity Securities on the issue date which may have an effect on the amount of funds raised by the issue of Equity Securities. 11 The table below is a hypothetical example of the potential dilution of existing Shareholders where the full 10% Share Placement Capacity is utilised, on the basis of three different assumed issue prices and values for variable “A” in the formula in ASX Listing Rule 7.1A.2. Dilution when compared with the current issued share capital Hypothetical issue price of shares issued under the 10% Share Placement Capacity 50% decrease in Issue Price $0.0355 per share Issue Price $0.071 per share 100% increase in Issue Price $0.142 per share Issued share capital Current issued share capital 402,722,697 10% dilution 40,272,269 shares 40,272,269 shares 40,272,269 shares Funds raised $1,429,665 $2,859,331 $5,718,662 50% increase in issued share capital 604,084,046 10% dilution 60,408,404 shares 60,408,404 shares 60,408,404 shares Funds raised $ 2,144,498 $ 4,288,996 $ 8,577,993 100% increase in issued share capital 805,445,394 10% dilution 80,544,539 shares 80,544,539 shares 80,544,539 shares Funds raised $ 2,859,331 $ 5,718,662 $ 11,437,324 Note: the table above has been prepared on the following assumptions: • The Issue Price of $0.071is based on the closing price of shares on 1 October 2026; • The current issued share capital of 402,722,697 Shares is the number of Shares on issue on 1 October 2026 and has been calculated in accordance with the formula in ASX Listing Rule 7.1A(2); • The Company issues the maximum number of Equity Securities available under the 10% Share Placement Capacity; • No Options or Rights are exercised prior to the date of issue of any Equity Securities; • The table shows only the effect of issues of Equity Securities under the 10% Share Placement Capacity, not under the Company’s 15% placement capacity under ASX Listing Rule 7.1; and • The table does not show an example of dilution that may occur to a particular Shareholder due to any placements under the 10% Share Placement Capacity. Approval Period An approval under ASX Listing Rule 7.1A commences on the date of the annual general meeting at which the approval is obtained and expires on the first to occur of the following: the date which is 12 months after the date of the annual general meeting at which the approval is obtained; • the time and date of the Company’s next annual general meeting; and • the time and date on which Shareholders approve a transaction under ASX Listing Rules 11.1.2 (significant change to the nature or scale of the Company’s activities) or 11.2 (disposal of the Company’s main undertaking). 12 Purpose of potential issue Any Equity Securities issued under the 10% Share Placement Capacity must be for cash consideration only. The Company presently intends to use any funds raised from such issues for working capital purposes. The Company will comply with its disclosure obligations under ASX Listing Rules 7.1A.4 and 3.10.3 upon any issue of Equity Securities. Allocation policy under the 10% Share Placement Capacity The Company’s allocation policy will depend on the prevailing market conditions at the time of any proposed issue under the 10% Share Placement Capacity. Potential allottees of Equity Securities under the 10% Share Placement Capacity will be determined on a case-by-case basis having regard to factors which may include: the methods of raising funds which are available to the Company, including the time and market exposure associated with the various methods of raising capital applicable at the time of the raising; • the effect of any such issue on the control of the Company; • the financial situation of the Company; and • advice from corporate, financial and broking advisers. At the date of this Notice, no specific intention to issue Equity Securities under the 10% Share Placement Capacity have been determined. If and when the determination is made to proceed with an issue of Equity Securities, the allottees may include existing and new Shareholders who are not related parties or associates of a related party of the Company. Prior issues and Shareholder approval The company confirms no Equity Securities were issued or agreed under ASX Listing Ru